Chantix, Pfizer's smoking-cessation drug, has been associated with more than 1,000 serious incidents and problems including diabetes, seizures and heart trouble, according to a report by the Institute for Safe Medication Practices based on an analysis of adverse events filed with the FDA. Pfizer said the existing label for Chantix is consistent with its safety profile.

Related Summaries